# Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures

> **NCT05738382** · PHASE2 · UNKNOWN · sponsor: **Bio Genuine (Shanghai) Biotech Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Assisted Reproductive Technology
- Controlled Ovarian Hyperstimulation

## Interventions

- **DRUG:** BG2109
- **DRUG:** Cetrorelix

## Key facts

- **NCT ID:** NCT05738382
- **Lead sponsor:** Bio Genuine (Shanghai) Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738382, "Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05738382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*